Xcellerex, Inc., along with three collaborators, has been awarded an $11 million Phase II contract by the Defense Threat Reduction Agency (DTRA) – Joint Science and Technology Office, Transformational Medical Technologies Initiative (TMTI), to develop technology for accelerated monoclonal antibody and vaccine manufacturing. Xcellerex is collaborating with Dowpharma, Biopharm Services, and deltaDOT. The team combines Xcellerex’s microbial PDMax high-speed process development and FlexFact...